Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non‑small‑cell lung cancer: A meta‑analysis of randomized controlled trials

Shen,Guodong; Bian,Geng; Yu,Haiying; Gao,Min; Kang,Dongmei; Shen,Gan; Hu,Shilian

doi:10.3892/mco.2013.210

Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non‑small‑cell lung cancer: A meta‑analysis of randomized controlled trials

Authors:
- Guodong Shen
- Geng Bian
- Haiying Yu
- Min Gao
- Dongmei Kang
- Gan Shen
- Shilian Hu
View Affiliations

Affiliations: Geriatrics Department, Anhui Provincial Hospital, Hefei, Anhui 230001, P.R. China, Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy, Hefei, Anhui 230001, P.R. China
Published online on: November 6, 2013 https://doi.org/10.3892/mco.2013.210
Pages: 146-150

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non‑small‑cell lung cancer (NSCLC) remains controversial. The aim of this study was to compare the VC and DC regimens in the first‑line treatment of advanced NSCLC. A search was conducted through PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and the Chinese Biomedical Literature database (CBM). The language of the publication was not considered to be a limitation. The recruited trials were evaluated for eligibility and quality and the data were extracted and analyzed. The endpoints were overall response, survival rate and toxicity. We analyzed 9 randomized controlled trials (RCTs), including a total of 1,886 patients. Patients receiving DC therapy exhibited a significantly higher response rate [relative risk (RR)=0.83, 95% CI: 0.73‑0.95 and P=0.007] and 2‑year survival rate (RR=0.65, 95% CI: 0.50‑0.84 and P=0.001). However, the 1‑year survival rate for the two cisplatin‑based regimens were comparable (RR=0.90, 95% CI: 0.81‑1.01 and P=0.07). Patients receiving the VC regimen more frequently developed grade 3̸4 leucopenia, anemia and vomiting, whereas those receiving DC chemotherapy were more prone to grade 3̸4 diarrhea. The incidence of grade 3̸4 neutropenia, thrombocytopenia and nausea were similar between the two arms. In conclusion, our study indicated that DC is superior to the VC regimen in terms of tumor response rate, 2‑year survival rate and safety for the first‑line treatment of advanced NSCLC.

View Figures

View References

1.	Parkin DM, Bray FJ and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2.	DeVita VT, Lawrence TS and Rosenberg SA: DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th Edition. Lippincott Williams & Wilkins; Philadelphia: 2009
3.	Montazeri A, Gillis CR and McEwen J: Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest. 113:467–481. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Abratt RP and Hart GJ: 10-year update on chemotherapy for non-small cell lung cancer. Ann Oncol. 17(Suppl 5): v33–v36. 2006.PubMed/NCBI
5.	Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
6.	No authors listed:. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995. View Article : Google Scholar : PubMed/NCBI
7.	Pujol JL, Barlesi F and Daurèsa JP: Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer. 51:335–345. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Ettinger DS, Bepler G, Bueno R, et al: Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 4:548–582. 2006.PubMed/NCBI
9.	Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar
10.	Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 12:360–367. 1994.
11.	Fossella F, Pereira JR, von Pawel J, et al: Randomised, multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Goffin J, Lacchetti C, Ellis PM, et al: First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol. 5:260–274. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar
14.	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
15.	Douillard JY, Gervais R, Dabouis G, et al: Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol. 16:81–89. 2005. View Article : Google Scholar
16.	Cui TJ, Liu ZH, Chen Z, et al: Comparisons among four chemo-therapy regimens for advanced non-small cell lung cancer. J Oncol (Chinese). 12:136–138. 2006.
17.	Chen YM, Perng RP, Shih JF, et al: A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan. Lung Cancer. 56:363–369. 2007.
18.	Li HM, Li HX, Liu KW, et al: Three chemotherapy regimens including cisplatin for advanced non-small cell lung cancer. J Shandon Univ China (Health Sci). 45:499–502. 2007.
19.	Wang R, Wang YL and Wang QC: A comparison of docetaxel plus cisplatin and vinorelbine plus cisplatin in 67 cases with advanced non-small-cell lung cancer. Bulletin Chin Cancer. 16:476–477. 2007.
20.	Song HP, Qiu WS, Xu JH, et al: First-line chemotherapy of docetaxel/cisplatin for advanced non-small cell lung cancer. Chin J Clin Oncol. 34:388–390. 2007.
21.	Tan EH, Rolski J, Grodzki T, et al: Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 20:1249–1256. 2009. View Article : Google Scholar
22.	Gebbia V, Lorusso V, Galetta D, et al: First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer. 69:218–224. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Auperin A, LePechoux C, Pignon JP, et al: Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1,764 patients. Ann Oncol. 17:473–483. 2006. View Article : Google Scholar : PubMed/NCBI
24.	D’Addario G, Pintilie M, Leighl NB, et al: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 23:2926–2936. 2005.PubMed/NCBI
25.	Lynch TJ, Patel T, Dreisbach L, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 28:911–917. 2010. View Article : Google Scholar : PubMed/NCBI